Global E-Clinical Solution Software Market Will Reach US$ 6,515.3 million in 2022

According to a new market report published by Persistence Market Research "Global Market Study on E-Clinical Solution Software: Asia to Witness Highest Growth by 2020", the global e-clinical solution software market was valued at US$ 3,005 Mn in 2014 and is expected to expand at a CAGR of 13.8% from 2014 to 2020, to reach US$ 6,515.3 Mn by 2020.

The global e-clinical solution software market is witnessing significant growth due to increasing clinical trials and R&D investments in pharmaceuticals and life science sectors. Increasing prevalence of diseases across the world is leading to rise in number of clinical trials. Various lifestyle-associated diseases and genetic disorders in the Middle East and North Africa have also led to increase in clinical trials in the respective regions.

Planning Forward? Access Sample Of E Clinical Solution Market Report! https://www.persistencemarketresearch.com/samples/2884

Company Profiles:

Oracle Corporation.
Merge Healthcare Incorporated.
Medidata Solutions Inc.
PAREXEL International Corporation.
BioClinica.
ERT.
OmniComm Systems Inc.
PHT Corporation.
DATATRAK International Inc.
CRF Health Inc.

How About Revitalizing The Strategy-Oriented Funnel To Stay Ahead In The E Clinical Solution Market? https://www.persistencemarketresearch.com/methodology/2884

In addition, the pharmaceutical industry is facing immense pressure to reduce the time consumed to conduct clinical trials and increase effect of drugs. Presence of various end users such as pharmaceuticals, clinical research organizations (CROs), and healthcare providers has increased the demand for e-clinical solution software. The global e-clinical solution software market was valued at US$ 3,005 Mn in 2014 and is expected to expand at a CAGR of 13.8% from 2014 to 2020 to reach US$ 6,515.3 Mn by 2020.

In North America, the average cost of research and development for a successful pharmaceutical drug continues to increase from pre-clinical stage i.e. initial development stage of drug till FDA approval i.e. launch of the drug in the market. According to Oracle Corporation - an e-clinical software company - the share of global clinical trials conducted in North America has reduced from 30% in 2006 to 19% in 2010.

This was due to complex regulatory and legal frameworks in North America, which led to shifting of the clinical trials market to developing countries such as India and China. This may lead to sluggish growth of clinical trials in the region.

Countries in Central and Eastern Europe provide abundant opportunities to life science companies for clinical development. According to Oracle Corporation - the percentage of clinical trials conducted in Western Europe has decreased from 25% to 19% and in Eastern Europe; the percentage has increased from 10% to 13% during 2006-2010.

However, Asia has become one of the fastest-growing markets for pharmaceutical products. Improved industry regulatory laws and patent expiration laws in various countries such as Japan, China, and India, have led to the expansion of the clinical trials market in Asia. Cost of conducting clinical trials in Asia is lower compared to that in Europe and the U.S.

Planning To Introduce An Offbeat Product/Technology In The E Clinical Solution Market? Go To "Purchase Now" To Have Our E Clinical Solution Market Report! https://www.persistencemarketresearch.com/checkout/2884

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.